Recent advances in neuroscience have illuminated the intricate interplay between brain network connectivity and clinical manifestations of neurodegenerative disorders. In a groundbreaking study led by Carini, Sommariva, Famà, and colleagues, published in the upcoming 2026 volume of npj Parkinson’s Disease, researchers employed network-based statistical methods to uncover a compelling association between heightened brain connectivity and the emergence of REM sleep behavior disorder (RBD) and hallucinations in the early stages of dementia with Lewy bodies (DLB). This revelation propels our understanding of early biomarkers and mechanistic pathways in DLB, a condition that has remained notoriously elusive in its prodromal phases.

Dementia with Lewy bodies is typified by a constellation of symptoms including cognitive fluctuations, parkinsonism, visual hallucinations, and pronounced sleep disturbances—particularly RBD, which involves abnormal enacting of dreams during rapid eye movement sleep. The pathological hallmark of DLB is the accumulation of alpha-synuclein protein aggregates, but the brain-wide functional implications of these inclusions have been difficult to delineate. This study provides a sophisticated network-level perspective, moving beyond regional atrophies or isolated dysfunction to investigate how abnormal synchronization within brain circuits corresponds with hallmark early symptoms.

Utilizing advanced neuroimaging techniques, the research team mapped whole-brain functional connectivity patterns in individuals clinically diagnosed with early DLB. By applying network-based statistics—a methodological approach designed to detect clusters of connections showing significant alterations—they identified a pervasive increase in connectivity in networks implicated in sensory processing and higher-order cognitive integration. This hyperconnectivity is particularly pronounced in regions governing visuospatial perception and executive control, both known to be vulnerable in DLB.

Equally important is the study’s focus on REM sleep behavior disorder, a parasomnia frequently predating the onset of cognitive decline in synucleinopathies. The findings reveal that patients exhibiting RBD demonstrated exaggerated connectivity within and between brainstem structures and cortical limbic circuits. This enhanced communication may reflect an aberrant attempt to compensate for neurodegenerative disruptions or could signify pathological network overexpression driving symptomatology such as dream enactment and vivid hallucinations.

Hallucinations, especially visual ones, are cardinal features distinguishing DLB from other dementias and represent a profound clinical challenge. The correlated increase in connectivity found in occipital and temporal networks—areas integral to visual processing and integration—offers a plausible neurophysiological substrate for these perceptual disturbances. The researchers propose that the observed network hyperconnectivity facilitates the aberrant sensory experiences characteristic of DLB hallucinations, providing a direct link between functional brain alterations and clinical phenomenology.

This comprehensive network approach underscores a paradigm shift in neurodegeneration research. Instead of emphasizing isolated regional alterations, the study advocates for a connectivity-centric view, situating brain function as an emergent property of dynamic, interconnected circuits. The utility of network-based statistics is harnessed here to quantify and localize meaningful patterns of connectivity change, thus refining diagnostic criteria and potentially guiding therapeutic targets targeting circuit-level dysfunctions.

The implications of this research are profound for early diagnosis and intervention in DLB. REM sleep behavior disorder is increasingly recognized as a prodromal marker, and the identification of brain network signatures associated with RBD and hallucinations heightens the possibility of earlier detection before overt cognitive decline. Early diagnosis could facilitate timely pharmacologic and non-pharmacologic strategies aimed at mitigating symptom progression and improving patient quality of life.

Moreover, these insights into the neurobiological underpinnings of hallucinations challenge existing models that primarily attribute these phenomena to neurotransmitter imbalances or isolated cortical atrophy. Instead, the data suggest a more complex mechanistic interplay where network-level dysfunctions amplify perceptual aberrations. This could inspire the development of novel interventions that focus on modulating specific brain circuits, perhaps through neuromodulatory techniques such as transcranial magnetic stimulation or targeted pharmacotherapies.

Methodologically, the use of robust network statistics distinguishes this study from prior investigations limited by regional approaches or simplistic connectivity metrics. The authors carefully controlled for confounding variables such as age, medication status, and cognitive severity, ensuring that observed connectivity increases are intrinsically linked to clinical symptoms rather than extraneous factors. Their analytic framework also differentiates between overall network increases and localized hyperconnected subnetworks, contributing to a nuanced understanding of disease mechanisms.

The study’s findings dovetail with emerging theoretical frameworks suggesting that neurodegenerative diseases involve dysregulated brain network homeostasis, whereby compensatory hyperconnectivity eventually succumbs to disconnection and network fragmentation. Understanding this temporal evolution could inform disease staging and the identification of “tipping points” amenable to intervention. Longitudinal studies will be critical to elucidate whether the increased connectivity observed in early DLB represents an adaptive or maladaptive response evolving over the disease course.

Importantly, this research integrates clinical phenotyping with cutting-edge neuroimaging data in a manner that is both mechanistically insightful and clinically relevant. The correlation of specific symptoms—RBD and hallucinations—with quantifiable network abnormalities bridges the gap between symptomatology and pathophysiology. Such integrative approaches exemplify precision medicine paradigms aiming to tailor diagnostics and treatments based on objective biomarkers.

While the focus on early DLB patients allows for the delineation of initial network alterations, further studies are warranted to explore how these connectivity patterns compare with related synucleinopathies such as Parkinson’s disease dementia or multiple system atrophy, as well as with Alzheimer’s disease. Cross-disorder comparisons could help identify disease-specific network signatures and refine differential diagnosis, a significant challenge in clinical neurology.

Additionally, future research should investigate how these connectivity changes interact with molecular markers, including alpha-synuclein burden and neuroinflammation, to construct a multi-level disease model. Integrating multimodal imaging data—structural MRI, PET, and functional connectivity—could unveil comprehensive maps linking proteinopathy, inflammation, and network dysfunction in DLB pathogenesis.

The innovative use of network-based statistics also opens avenues for evaluating treatment responses. Monitoring connectivity alterations longitudinally in patients undergoing pharmacological or behavioral interventions could identify biomarkers predictive of therapeutic efficacy or progression. This might be particularly relevant given recent interest in targeting sleep disturbances and hallucinations therapeutically in DLB.

As brain connectomics continues to mature, its application in neurodegenerative disorders offers transformative potential. By reframing DLB symptoms within network dynamics, this study not only advances scientific understanding but also brings hope for novel diagnostic and therapeutic approaches to a devastating disorder. The findings underscore the critical role of interdisciplinary research merging neuroimaging, clinical neurology, and computational neuroscience.

In summary, the work by Carini and colleagues represents a landmark contribution delineating how increased brain connectivity correlates with REM sleep behavior disorder and hallucinations in early dementia with Lewy bodies. Their sophisticated use of network-based statistics provides compelling evidence that hyperconnected cerebral and brainstem circuits underlie core symptomatic phenomena, offering mechanistic insight and potential clinical utility. These results herald a new era of connectivity-centric biomarker discovery and intervention strategies for synucleinopathies.

This study exemplifies how leveraging network neuroscience can unravel complex neurodegenerative disease processes, moving the field beyond traditional diagnostic constraints and toward personalized medicine based on dynamic brain circuit function. Continued exploration of network abnormalities promises to unlock further mysteries of dementia with Lewy bodies and related disorders, ultimately benefiting patients through improved diagnosis and treatment.

Subject of Research: Functional brain network connectivity alterations associated with REM sleep behavior disorder and hallucinations in early dementia with Lewy bodies.

Article Title: Network based statistics associates increased connectivity to REM sleep disorder and hallucinations in early DLB.

Article References:
Carini, L., Sommariva, S., Famà, F. et al. Network based statistics associates increased connectivity to REM sleep disorder and hallucinations in early DLB. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01412-w

Image Credits: AI Generated

RBD has long been recognized as a prodromal marker of Parkinson’s disease, characterized by the loss of normal muscle atonia during REM sleep, leading to vivid dream-enactment behaviors that are often violent or disruptive. While this symptomatology affects a subset of Parkinson’s patients, it does not encompass the full spectrum of sleep disruptions experienced. The latest research, published in npj Parkinson’s Disease, employs advanced neurophysiological techniques combined with high-resolution polysomnography and novel biomarker analytics to detect covert abnormalities in REM sleep that precede or accompany clinical Parkinsonism but are distinct from overt RBD.

By examining a cohort of early-stage Parkinson’s patients and carefully matched healthy controls, the researchers identified subtle but reproducible alterations in REM sleep microarchitecture. These alterations include fragmented REM sleep cycles, abnormal spectral dynamics in EEG oscillations during REM, and shifts in functional connectivity within and between key brainstem nuclei and cortical areas involved in sleep regulation. Such covert disturbances, undetectable through traditional sleep staging methods, suggest an insidious disruption of REM sleep control systems that may reflect underlying neurodegenerative processes affecting cholinergic and monoaminergic pathways essential for REM generation and maintenance.

Interestingly, the study highlights that these covert REM abnormalities are present even in patients who do not meet clinical criteria for RBD, broadening the conceptual framework around sleep dysfunction in Parkinson’s disease. This suggests that covert REM dysfunctions may represent a prodromal or parallel non-motor feature, contributing to the cognitive and affective symptoms frequently observed in PD. The interplay between these covert anomalies and the severe dream-enactment behaviors seen in classical RBD remains an open area of investigation, with implications for prognosis and personalized intervention strategies.

Furthermore, the authors employed cutting-edge machine learning algorithms to analyze the complex EEG data, enabling the detection of subtle REM alterations that traditional analytic approaches might miss. This computational approach not only enhances diagnostic sensitivity but also allows for the quantification of REM sleep disruptions on a continuum, facilitating longitudinal studies of disease progression and therapeutic response. Such methodologies could revolutionize sleep research in neurodegenerative disorders, bridging the gap between subjective symptom reports and objective physiological markers.

At the cellular level, Parkinson’s disease is defined by the loss of dopaminergic neurons in the substantia nigra pars compacta, yet sleep circuitry involves an intricate network of brainstem nuclei including the pedunculopontine and laterodorsal tegmental nuclei, regions rich in cholinergic neurons critical for REM phenotype expression. Pathological changes in these nuclei, as reflected by the covert sleep abnormalities detected, suggest that neurodegeneration in PD extends beyond dopaminergic systems, encompassing multifaceted neurotransmitter disruptions that contribute to sleep and circadian rhythm disturbances.

The clinical significance of these findings lies in their potential utility as early biomarkers. Sleep dysfunction often antecedents motor symptom onset, and covert REM abnormalities detectable via non-invasive polysomnographic recordings could serve as an early warning system. This would enable clinicians to identify at-risk individuals before irreversible motor impairment, opening a therapeutic window for neuroprotective interventions. Additionally, characterizing these sleep disruptions may improve patient stratification in clinical trials, leading to more tailored and effective treatments.

This study also underscores the need to rethink patient management paradigms. Currently, sleep disturbances in Parkinson’s are frequently underdiagnosed and undertreated, particularly subtle or subclinical forms. Increased awareness and application of advanced sleep assessment tools could vastly improve quality of life, as REM sleep integrity is essential not only for physical restoration but also for cognitive function, memory consolidation, and emotional regulation—domains often compromised in PD.

Moreover, the implications extend beyond Parkinson’s disease. Similar covert REM abnormalities might be present in related neurodegenerative diseases characterized by Lewy body pathology, such as dementia with Lewy bodies and multiple system atrophy. Comparative investigations could help determine whether these sleep disruptions are disease-specific or represent a shared pathophysiological feature, enriching our understanding of neurodegenerative sleep neurobiology and guiding cross-disease therapeutic approaches.

The study further touches on mechanistic insights into REM sleep regulation, revealing how subtle synaptic and network dysfunctions could present as macrostructural sleep abnormalities. Disruptions in GABAergic and glutamatergic transmission within REM-generating circuits may underlie the fragmented and aberrant EEG profiles observed, suggesting targets for pharmacologic modulation. Targeted therapies aiming to restore balanced neurotransmission during REM could alleviate sleep-related symptoms and potentially slow neurodegeneration.

Crucially, this research highlights the sophistication of modern neuroimaging and electrophysiological techniques. Combining high-density EEG with functional MRI, alongside neurochemical probes, creates a multidimensional picture of how brain function deteriorates in Parkinson’s disease. These integrated approaches set a new standard for investigating sleep disorders as integral components of neurodegenerative illness, rather than peripheral complications.

Patient narratives and qualitative data further enrich the significance of these covert REM abnormalities. Many PD patients report fragmented and nonrestorative sleep despite lacking overt RBD signs, a discrepancy now better explained by the identification of subclinical REM disruptions. Recognizing and validating these experiences reinforces the need for comprehensive sleep assessments within routine Parkinson’s care protocols.

Additionally, the study prompts exciting translational possibilities. Development of wearable sleep monitoring devices capable of capturing and analyzing covert REM abnormalities in real-world settings could enable continuous assessment, facilitating early diagnosis and real-time therapeutic adjustments. Integration with digital health platforms may empower patients to participate actively in disease management, promoting personalized medicine in Parkinson’s disease.

Looking forward, longitudinal follow-up studies are essential to clarify whether covert REM sleep abnormalities predict the evolution of motor and cognitive symptoms in Parkinson’s. Determining causality and temporal dynamics between REM disruptions and neurodegeneration will crucially influence therapeutic timing and the development of disease-modifying interventions aimed at preserving brainstem integrity.

In sum, Lanir-Azaria and colleagues have broken new ground by demonstrating that REM sleep abnormalities in Parkinson’s extend well beyond the overt phenomena captured by RBD diagnosis. Their work illuminates a hidden layer of pathology that may be key to unlocking earlier detection, better symptom management, and ultimately more effective disease-modifying therapies. As our understanding deepens, the realm of sleep research stands poised to transform the clinical landscape of Parkinson’s disease, underscoring the vital interconnection between sleep and neurodegeneration.

Subject of Research: Parkinson’s disease-related REM sleep abnormalities beyond classical REM sleep behavior disorder (RBD).

Article Title: Beyond RBD: covert REM sleep abnormalities in Parkinson’s disease.

Article References:
Lanir-Azaria, S., Nir, Y., Tauman, R. et al. Beyond RBD: covert REM sleep abnormalities in Parkinson’s disease. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01295-x

Image Credits: AI Generated

The 39th annual meeting of the Associated Professional Sleep Societies—SLEEP 2025—held from June 8-11 in Seattle, showcased pioneering research by sleep medicine experts from Mount Sinai Health System. These researchers are driving cutting-edge advances in understanding how sleep intricacies impact memory consolidation, neurodegenerative diseases, cardiometabolic health, and beyond. Their findings, published in an online supplement of the journal Sleep, are poised to reshape how clinicians and scientists approach sleep-related disorders and their systemic consequences.

The spectrum of research presented encompasses urgent questions regarding the physiological mechanisms underlying sleep and its disruption. A notable presentation by Dr. Andrew W. Varga addressed whether the failure of the brain’s cleaning processes during sleep—critical to the brain’s waste clearance through the glymphatic system—is a causal factor in Alzheimer’s disease. By dissecting the complex interaction between sleep architecture and cerebral proteostasis, this work provides novel insights into potential therapeutic targets for neurodegeneration.

On another front, Dr. Emmanuel During focused on biomarker updates related to REM Sleep Behavior Disorder (RBD), leveraging neurophysiology, actigraphy, and biofluid markers. Their work highlights how robust multimodal biomarker identification can facilitate earlier and more precise diagnosis of RBD, a condition with profound links to synucleinopathies such as Parkinson’s disease and dementia with Lewy bodies. This approach dovetails with computational advancements utilizing actigraphy-based classifiers, aiming for non-invasive, scalable screening.

Investigations into sleep apnea’s impact on neurodegeneration were featured prominently. Drs. Korey Kam and Anna Mullins discussed the differential effects obstructive sleep apnea (OSA) exerts on Alzheimer’s pathogenesis, emphasizing physiological, racial, and sex-specific mechanisms. Their symposium underscored how OSA’s intermittent hypoxia and sleep fragmentation may accelerate neurodegenerative cascades, with critical variance influenced by demographic factors.

Several poster presentations delved into the intersection between sleep physiology and cognitive function across lifespan and disease states. For instance, Anjona Datta and Daphne Valencia examined the influence of REM-specific OSA and hypoxic burden on sleep-dependent spatial navigational memory and white matter integrity in cognitively normal elderly adults. Their use of diffusion tensor imaging (DTI) elucidates microstructural brain alterations that may underlie cognitive decline linked to sleep-disordered breathing.

Furthermore, research by Anna Mullins explored how encoding opportunities and slow wave activity during sleep modulate spatial memory consolidation in older adults. This study tackles the decline in sleep microstructure with age, proposing that amplified encoding before sleep can mitigate cognitive deterioration effects, a finding with profound implications for interventions in aging populations.

Animal model research by Kerly Lozano investigated early adult sleep disruption in PS19 tauopathy mice, tracking longitudinal changes in spatial learning, neuroinflammation, and tau pathology. This translational work strengthens the mechanistic understanding of how sleep deficiencies influence tau-mediated neurodegeneration, bolstering arguments for prioritizing sleep health in Alzheimer’s disease prevention.

On the technology and methodology front, Benjamin Fox and Sajila Wickramaratne presented the creation of a Transformer-based machine learning model that processes full-night multichannel polysomnographic data to predict cardiovascular mortality risk. This innovation represents a leap forward in detecting cardiometabolic risks rooted in sleep disorders, illustrating the confluence of artificial intelligence and biomedical data for predictive healthcare.

Automated scoring techniques were critically evaluated in studies such as Dr. Thomas Tolbert’s comparison of automated versus manual arousal threshold estimation using polysomnography. Automated methods based on EEG power enhance phenotyping accuracy and efficiency in OSA endotyping, potentially transforming clinical sleep diagnostics.

Exploring demographic nuances, Sarah Chu analyzed physiological burdens of OSA across diverse populations from the Sleep Heart Health Study and Multi-Ethnic Study of Atherosclerosis. She revealed how emerging respiratory metrics vary with age, sex, and race/ethnicity, underscoring the necessity for tailored diagnostic criteria and personalized treatment strategies.

Additional studies investigated the locus coeruleus structural integrity in older adults with OSA through ultra-high field 7 Tesla MRI, linking sleep apnea to neurodegeneration markers in this crucial brainstem region involved in arousal regulation. Such neuroimaging advances provide unprecedented resolution to examine subtle pathological changes early in disease progression.

Efforts to validate non-invasive sleep monitoring tools were also emphasized, as shown by Daphne Valencia’s assessment of the WatchPAT device’s diagnostic accuracy against concurrent polysomnography in older adults—a critical step toward accessible, community-based sleep disorder assessments.

Sleep irregularity’s connections to cardiometabolic health were dissected by Bolong Xu using actigraphy and PET/MRI imaging, revealing associations between disrupted sleep patterns and vascular inflammation independent of OSA, highlighting novel pathways by which sleep disturbances contribute to cardiovascular disease.

Mount Sinai researchers also spotlighted specialized populations, including World Trade Center rescue workers, with studies linking chronic rhinosinusitis to insomnia symptoms and cognitive impairment, echoing the importance of addressing comorbidities influencing sleep in vulnerable groups.

In the evolving landscape of sleep disorder assessments, Dr. Emmanuel During’s late-breaking research includes developing automated RBD severity rating with computer vision and machine learning classifiers for prodromal synucleinopathy screening, offering scalable solutions for early intervention in neurodegenerative diseases.

Taken together, Mount Sinai’s presentations at SLEEP 2025 represent a comprehensive, multi-disciplinary assault on the mysteries of sleep and its far-reaching effects on neurological and systemic health. Integrating advanced imaging, neurophysiology, bioinformatics, and clinical insights, these studies pave the way toward diagnostic and therapeutic innovations targeting sleep as a pillar of wellness and disease prevention.

Subject of Research: Sleep physiology, neurodegenerative diseases, obstructive sleep apnea, biomarkers, machine learning in sleep medicine.

Article Title: Sleep Medicine Breakthroughs from Mount Sinai Experts Revealed at SLEEP 2025 Conference

News Publication Date: June 8, 2025

Web References:

• https://www.sleepmeeting.org
• https://academic.oup.com/sleep/article/48/Supplement_1

Image Credits: The Mount Sinai Health System

Keywords: Sleep, REM sleep, Sleep deprivation, Neurodegenerative diseases, Alzheimer disease, Parkinson’s disease, Cognitive disorders, Dementia, Sleep apnea